Apps

ADAR1 Capital Expands Biotech Portfolio Across Five Stocks — Aug 25, 2026ADAR1 Capital Management LLC disclosed new positions in five biopharma names in Q2, including sizable buys of ACADIA Pharmaceuticals, Adagio Medical, Larimar Therapeutics, Artiva Biotherapeutics, and Corvus Pharmaceuticals, with investment values ranging from roughly $785,000 to over $1.9 million. The ACADIA stake coincides with the European Commission’s approval of DAYBU for Rett syndrome, signaling potential expansion into a key EU market for the company.

Electra Therapeutics Prices $350 Million Biotech IPO — 2dElectra Therapeutics priced an upsized $15-per-share IPO at roughly $350 million, selling 23,333,334 shares with a 30-day option for 3.5 million more and set to trade on Nasdaq as ETRA; proceeds will fund its ipsoprubart HLH program and other candidates as it scales its late-stage pipeline. The deal underscores strong investor demand for biotech IPOs in 2026, with Electra among multiple companies raising substantial capital for immune-mediated diseases and cancer programs.

Sam Okafor The proceeds should help push their late-stage candidates forward, though execution risk in biotech remains high.

Legend Biotech names Novartis executive Ingrid Zhang CEO — 4dLegend Biotech appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, with interim CEO Alan Bash becoming President of CARVYKTI. Zhang, a former Novartis executive and China head, brings broad global leadership experience from AstraZeneca, Pfizer, and McKinsey as the board positions Legend for its next growth phase.

Tom Gallagher Hiring someone with McKinsey and AstraZeneca experience signals the board wants tighter global operations going forward.

Companies Plan Presentations at H.C. Wainwright ConferenceBusiness — Sep 8, 2026Multiple biotech and mining firms announced participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York this fall, with senior executives set to present or engage in investor meetings to raise visibility. Included are Assembly Biosciences, Nanobiotix, Artelo Biosciences, Fortress Biotech, and U.S. Gold Corp, each outlining presentations or project highlights and strategic discussions.

Biotech firms award new hires stock options, some worth hundreds of thousands — Aug 31, 2026Several biopharma and biotech companies—X4 Pharmaceuticals, Aura Biosciences, Akebia Therapeutics, Abeona Therapeutics, and Faeth Therapeutics—awarded inducement equity grants to newly hired executives or employees under Nasdaq Listing Rule 5635(c)(4), including stock options (with Aura also granting RSUs) and with 10-year terms and multi-year vesting schedules designed to align new hires with company goals. Vesting generally starts with 25% after one year and proceeds in monthly or quarterly installments over the following three years, subject to continued employment, with exercise prices set to the grant-date closing price.

Biotech Firms Plan Global Investor ConferencesHealth — Aug 31, 2026Multiple biotech companies announced management participation in upcoming investor conferences, including Surrozen, Ascentage Pharma, Alpha Tau, Nurix Therapeutics, and Processa Pharmaceuticals. Surrozen will present at two healthcare conferences; Ascentage Pharma will participate in four; Alpha Tau’s CFO will attend multiple investor meetings; Nurix will host fireside chats; and Processa will present at Wells Fargo’s and H.C. Wainwright’s conferences following its Vidya Therapeutics acquisition.

Veraxa Biotech Names Raju Willener CFO Amid Funding Challenges — Sep 4, 2026VERAXA Biotech appointed Raju Willener as chief financial officer, signaling governance stability and a strengthened capital strategy for a pre-revenue oncology company that relies on a SPAC de-SPAC and a $77.5 million funding package to support its BiTAC platform while its first candidate targets IND/CTA readiness in 2028. Willener's three-plus decades of global capital markets and corporate-finance leadership will guide the company’s funding, M&A and financial operations as it advances its pipeline and investor relations.

Nicole Hardy for IND readiness is a long runway. Hope that $77.5M actually lasts that far with no revenue coming in.

White House plans new biotech drug pricing deals — Aug 26, 2026The White House under the current president is preparing new voluntary drug-pricing deals with mid-sized biotech firms to lower outpatient Medicaid costs by aligning prices with international benchmarks, offering relief from certain Medicare pilot programs and possible tariff concessions. The initiative, framed as healthcare affordability ahead of the elections, follows prior similar agreements and is expected to include a new announcement around August 31, 2026.

Vir Biotechnology appoints Brent Sabatini Interim CFO — Jul 24, 2026Vir Biotechnology named Brent Sabatini as interim principal financial officer after Jason O’Byrne’s departure, with O’Byrne remaining through August 3 to ensure a smooth transition and a search for a permanent CFO underway. Sabatini, currently SVP and Chief Accounting Officer, brings more than two decades of finance and accounting experience and is expected to maintain continuity in financial oversight during the leadership change.

CNTN completes Gravitas sale, refocuses strategy — Jul 23, 2026Canton Strategic Holdings completed the sale of its Gravitas Life Sciences biotech unit to Gravitas Collective Corp, a deal approved by a special independent committee and closed in mid-July 2026, shifting the company away from biotech toward its Canton Network and digital-asset initiatives. The move aims to streamline operations, boost focus on digital assets and GV104, and is complemented by governance safeguards and a renewed emphasis on blockchain infrastructure, with insiders having minimal recent activity on the stock.

Trinity Biotech, Latch Medical announce CGM+ drug-delivery partnership — Jul 22, 2026Trinity Biotech and Latch Medical have announced a strategic collaboration to integrate Trinity’s AI-native CGM+ wearable biosensor with Latch’s Pharma Latch intradermal drug-delivery platform to guide precise injectable therapies for diabetes, obesity, and other metabolic conditions, aiming to create an AI-guided metabolic health platform. Trinity also plans a strategic equity investment in Latch as part of advancing regulatory-ready, biosensor-informed treatment approaches.

Trinity Biotech Plans 1-for-30 Reverse ADS Split to Meet Nasdaq — Jul 22, 2026Trinity Biotech plans a 1-for-30 reverse ADS split, changing from 1 ADS for 20 Class A shares to 1 ADS for 600 Class A shares, to regain Nasdaq’s $1 minimum bid price and attract a broader investor base, with the move taking effect around July 24, 2026. The announcement followed by a dash in premarket trading and comes amid concerns over the company’s weak finances and profitability, which have kept the stock trading at depressed levels.

Longevity Interest Spans Health, Medicine, InvestmentHealth — 6dExperts caution that longevity should be defined by reducing risks of cardiovascular, metabolic, cancer and cognitive diseases through comprehensive testing and personalized plans, not merely chasing arbitrary biological age scores. The conversation across clinics, media voices and investors now spans practical skin- and device-based improvements, measured prevention through the Silent Decade framework, and bold biotech funding aimed at replacement therapies and long-term durability.

United Therapeutics and Denali Outline Pipeline Shifts at Morgan Stanley Conference — 5dBiotech firms Crescent Biopharma, Denali Therapeutics, Kyverna Therapeutics, and United Therapeutics outlined forthcoming data, new indications, and expansive commercial strategies at the Morgan Stanley Global Healthcare Conference, signaling a push into pulmonary fibrosis, CNS, and other large patient populations. Denali highlighted its Avlayah Transport Vehicle platform and CNS programs, while United Therapeutics outlined a four‑product strategy for IPF/PPF and planned NDA activities, underscoring continued innovation and manufacturing expansion across the sector.

Nicole Hardy Shifting focus to larger populations like pulmonary fibrosis makes sense for growth but competition will be fierce.

Stoke, Biogen report four-year zorevunersen data showing sustained seizure control — Sep 1, 2026At the European Epilepsy Congress in Athens, Stoke Therapeutics and Biogen presented four-year data from Phase 1/2a open-label extensions showing sustained cognitive and behavioral improvements plus durable seizure reductions for zorevunersen in Dravet syndrome, with results supporting ongoing Phase 3 EMPEROR and an anticipated 2027 readout. Separately, GRIN Therapeutics announced its on-site participation at the congress to discuss progress on GRIN-related neurodevelopmental disorders and potential collaborations, underscoring ongoing activity in epilepsy-focused biotech development.

Sam Okafor Good to see multiple companies like GRIN Therapeutics also active at this congress, feels like real momentum building in the rare epilepsy space.

Lilly Plans $2.88B Merida Autoimmune AcquisitionBusiness — Sep 3, 2026Eli Lilly is rapidly expanding beyond its obesity-and-diabetes blockbuster lineup, striking two multi-deal paths: a $2.875 billion-plus acquisition of Merida Biosciences to broaden its autoimmune and antibody-directed therapies, and a $3.83 billion spree to acquire three biotech firms—Curevo, LimmaTech Biologics, and Vaccine Company—to build a broader vaccine and infectious-disease pipeline. The moves underscore a strategy to diversify growth into immunology, infectious diseases, and autoantibody therapies while managing revenue risk from reliance on a small number of weight‑loss drugs.

Lee Jae Myung to visit France for Lumière Summit and broader talks with Macron — Sep 4, 2026South Korea’s presidents, Lee Jae Myung and Yoon Suk Yeol, will travel to France from September 6 to 9 to co-chair the Lumière Summit with President Macron and engage in a series of bilateral and multilateral events aimed at expanding K-content and European partnerships across film, AI, space, biotech, and other advanced industries. The trips are pitched as steps to deepen Korea–France strategic ties and broaden Korea’s diplomacy with Europe, including high-level meetings, business roundtables, and state‑level ceremonies.

Chris Dalton K-content plus AI and biotech partnerships with France sounds promising, curious what actually comes out of the roundtables.

Small-cap stocks rally as RedHill, Peraso and LogProstyle land new deals — Sep 1, 2026A cluster of small-cap moves centers on RedHill Biopharma divesting Talicia to Apotex for upfront cash and potential milestone payments, improving liquidity for expansion; Peraso is positioned to benefit from the Army’s Infantry Last Tactical Mile via 60GHz mmWave tech for secure communications in autonomous systems; LogProstyle approves the acquisition of Japan’s I-FLATZ to broaden its real estate footprint into Kansai; Webuy Global reports record performance as these firms collectively reflect diversification in biotech, defense tech, real estate, and AI-enabled travel.

Nicole Hardy LogProstyle expanding into Kansai via I-FLATZ is a smart regional play, Japan's real estate market rewards local density over spreading thin nationally.

Roche seals $1.53B Simcere trispecific deal — Sep 1, 2026Roche agreed to pay $75 million upfront to acquire exclusive global rights to SIM0660, a preclinical trispecific antibody from Simcere Zaiming that targets CD79a, CD19 and CD3, with total potential payments up to $1.53 billion and tiered royalties up to double digits. The therapy is designed to trigger T-cell–mediated killing across B-cell–mediated diseases, including autoimmune conditions, highlighting a growing collaboration between Roche and a Chinese biotech.